Celgene (CELG) Partner Acceleron Initiates ACE-536 Phase 2

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

Acceleron Pharma, Inc., announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart. Patients and healthcare providers currently have limited options for the treatment of beta-thalassemia. This is the second ongoing Phase 2 trial for ACE-536, which is being developed by Acceleron as part of a global collaboration with Celgene Corporation (Nasdaq: CELG).

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Celgene (CELG) Granted FDA Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer
• Biogen Idec (BIIB) Appoints Spyros Artavanis-Tsakonas as CSO
• Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?